Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACM Research Inc (ACMR) vs Becton Dickinson and Co (BDX) Price & Performance

ACM Research IncTrade
Becton Dickinson and CoTrade

Price performance (Past 24H)

Key statistics

ACM Research Inc vs Becton Dickinson and Co — how do they compare? ACM Research Inc trades at $83.07 (market cap $5.57B), while Becton Dickinson and Co trades at $179.18 (market cap $49.41B). The key difference: Becton Dickinson and Co is far larger — about 8.9× ACM Research Inc's market cap, and Becton Dickinson and Co pays a 2.32% dividend while ACM Research Inc pays none. Which is the better fit depends on your goals.

ACMRBDX
Market Cap
$5.57B$49.41B
Sector
TechnologyHealth
52-Week High
$126.89$185.39
52-Week Low
$24.93$138.62
Enterprise Value
$4.48B$65.51B
Dividend Yield
2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACM Research Inc

ACMR trades at $83.03, up 4.56% in the last session, with a neutral technical signal and bearish moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.61 versus $0.42 expected, and revenue grew 36% year-over-year to $292.9 million. The company raised its 2026 revenue guidance amid strong order growth of 105% in the first half, driven by new products like the Ultra C Tahoe wet processing platform expansion announced on August 7, 2026.

Outlook is positive with 80% analyst buy ratings and a consensus price target of $127.50, implying 54% upside. Risks include high valuation with a P/E of 37.7 and reliance on semiconductor cycle demand. Net cash flow improved to $538 million in 2026 from $355 million in 2025, supporting growth initiatives.

Becton Dickinson and Co

BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.

The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACM Research Inc

ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.

Read more on ACMR

About Becton Dickinson and Co

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Read more on BDX